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Abstract Spontaneous bacterial peritonitis (SBP) is a
common cause of morbidity and mortality in patients with
advanced cirrhosis and portal hypertension. While gram-
negative rods and Enterococcus species are the common
offending organisms, Salmonella has also been recognized
as a rare and atypical offending organism. Atypical features
of Salmonella SBP include both its occurrence in cirrhotic
patientswithimmunosuppressivestateanditslackoftypical
neutroascitic response. Diagnosis is often delayed as it
requires conﬁrmation from ascitic ﬂuid culture. We report a
case of Salmonella SBP occurring in a patient with decom-
pensated cryptogenic cirrhosis with concurrent low-grade
non-Hodgkinlymphomaandpriortreatmentwithrituximab.
Physicians should be aware of the atypical presentation,
especially in cirrhotic patients who are immunosuppressed.
Keywords Spontaneous bacterial peritonitis 
Rituximab  Live donor liver transplant  Cirrhosis
Introduction
Spontaneous bacterial peritonitis (SBP) due to Salmonella
is uncommon in cirrhotic patients with ascites, and it is
often associated with an immunosuppressed state and often
presents without typical signs or symptoms of SBP [1, 2].
We report a case of SBP due to group B Salmonella in a
patient with decompensated cryptogenic cirrhosis and
portal hypertension.
Case
A 61-year-old female Arab patient was referred to our
center for management of decompensated cryptogenic liver
cirrhosis. She has type II diabetes mellitus since adoles-
cence and hypertension of 5 years’ duration. She was also
diagnosed with B-cell follicular non-Hodgkin lymphoma
(NHL), stage IIIA, involving gastric mucosa and abdomi-
nal lymph nodes, 8 months ago. She was treated with
rituximab (anti-CD20 monoclonal antibodies) and dexa-
methasone. However, she developed grade IV hepatic
encephalopathy after three cycles of rituximab and che-
motherapy was stopped.
Since the onset of encephalopathy, she started com-
plaining of worsening ascites and lethargy, and had two
more episodes of grade IV hepatic encephalopathy. By
February 2008, she was referred to our center for evalua-
tion for live donor liver transplantation (LDLT). She had
no history of variceal bleeding or SBP and was not on
prophylactic antibiotics. Initial physical examination
showed moderate ascites and bilateral ankle edema, with
normal chest and heart examinations. Blood tests showed
normal creatinine and electrolytes, bilirubin 82 uM, albu-
min 26 g/l, alanine transaminase 22 U/l, aspartate
transaminase 43 U/l, and alkaline phosphatase 73 U/l.
Complete blood cell count showed slightly low hemoglo-
bin at 11.3 g/dl, low platelets at 65,000/mm
3, and normal
white cells at 5,050/mm
3. INR was elevated at 1.31.
Computed tomographic (CT) scan revealed cirrhotic liver,
splenomegaly, moderate ascites, and small, subcentimeter
retroperitoneal lymphadenopathy. No gallstones were seen
on CT or ultrasound scan. Positron emission tomography
CT scan did not reveal any ﬂuorodeoxyglucose-avid
lesions to suggest active lymphoma, and ascitic ﬂuid
cytology was negative for lymphoma cells.
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complained of acute onset of generalized abdominal pain.
There was no fever, diarrhea, vomiting, or urinary symp-
toms. Clinically, she was afebrile and did not have
tachycardia, but there was right-sided abdominal tender-
ness. A diagnosis of SBP was suspected and the patient was
admitted for diagnostic paracentesis and empiric antibiotics
therapy. Urinalysis and urine culture were unremarkable.
Initial ascitic ﬂuid analysis results showed a leukocyte
count of 110/mm
3, majority being lymphocytes, with lac-
tate dehydrogenase, protein, and albumin at 54 U/l, 11 g/l,
and 5 g/l, respectively. Her serum ascitic albumin gradient
was 21 g/l, consistent with signiﬁcant portal hypertension.
However, 2 days later, ascitic ﬂuid culture showed pres-
ence of group B Salmonella, which was sensitive to both
ceftriaxone and ciproﬂoxacin. She was treated with an
intravenous dose of ceftriaxone for a week followed by an
oral dose of ciproﬂoxacin. Intravenous albumin infusion
was also given concurrently to prevent renal impairment.
Subsequent blood and stool cultures did not show growth
of any organisms. She recovered well from the infection,
with resolution of abdominal pain and tenderness; she
underwent LDLT 2 weeks after diagnosis of Salmonella
SBP. During laparotomy, no intra-abdominal lymphade-
nopathy was noted and explant liver did not show any
evidence of active lymphoma. She has been recovering
well from the transplant and remained well at her last
follow-up 6 weeks posttransplant.
Discussion
SBP is a common complication of patients with decom-
pensated cirrhosis, occurring in 10% to 30% of cirrhotic
patients with ascites, with a mortality of up to 30%.
Standard investigation includes ascitic ﬂuid analysis for
cell count analysis, biochemical analysis, and cultures.
Third generation cephalosporins with intravenous albumin
infusion are the standard treatment. Deﬁnitive diagnosis
does not require a positive culture because an ascitic ﬂuid
neutrophil count of more than 250/mm
3 is sufﬁcient for
diagnosis, as culture results often take a minimum of 48 h
to be available [3, 4].
Common offending organisms in SBP are Klebsi-
ella pneumoniae, Escherichia coli, and Enterococcus
species [5, 6]. Non-typhoidal Salmonella is a rare cause of
SBP. Previous case series reported various immune-com-
promised states, such as AIDS and non-hepatic cancer, as
risk factors for Salmonella SBP [1, 2]. In our patient, her
immunosuppressive state could be related to her prior
administration of rituximab, an anti-CD20 monoclonal
antibody. Depletion of peripheral B lymphocytes,
important for humoral response to bacterial antigens, has
been shown to last for up to 2 years after its administration
[7, 8]. In addition, her underlying low-grade NHL and
diabetes mellitus may have also contributed to her immu-
nosuppressive state.
Salmonella SBP is an unusual form of SBP as it has also
been reported to be asymptomatic, with no overt systemic
signs of infection. There may be little biochemical evi-
dence, or neutroascitic response in ascitic ﬂuid analysis,
and the diagnosis often requires conﬁrmation on ascitic
ﬂuid culture [3]. As seen in our patient, her only symptom
was abdominal pain and initial ascitic ﬂuid analysis did not
reveal any neutroascitic reaction or elevation of lactate
dehydrogenase and conﬁrmation of SBP was made only
48 h later when ascitic culture results returned.
In summary, we reported a case of a cirrhotic patient
who was immunosuppressed from follicular NHL and prior
use of rituximab, presenting atypically for SBP that was
subsequently diagnosed as Salmonella SBP. Physicians
should be aware of this atypical presentation and routine
ascitic ﬂuid culture should be performed in patients sus-
pected of having SBP, particularly in cirrhotic patients with
an immunosuppressive state.
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